Although the combination of hypofractionated stereotactic radiotherapy (hFSRT) and anti-PD-L1 therapy has shown initial promise in the treatment of glioblastoma, with good tolerability and disease control, further research is needed to enhance its efficacy, particularly in overcoming the intrinsic immunosuppressive nature of GBM. The gene discussed is CD274; the disease is glioblastoma.